Form D · Biotechnology
RYNE Biotechnology Inc.
Cambridge, MA · CIK 0001938657
Offering snapshot reported Mar 1, 2024 · SEC filing
- Reported sold
- $30M Offering amount: $81.8M
- Investors reported
- 9 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- Feb 26, 2024 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Mar 1, 2024 | Initial | $30,000,000 | No comparison | 9 | SEC filing |
| Jul 20, 2022 | Initial | $3,000,000 | No comparison | 1 | SEC filing |
Offering details
- Securities
- Equity, Security to be acquired
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-506550
A portion of the Total Offering Amount and Total Amount Sold was comprised of the cancellation and conversion of certain indebtedness or other conversion instrument previously issued by the Company.
Source: Form D, filed Mar 1, 2024. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Carter Cliff | Director |
| David Fallace | Director |
| Howard Federoff | Director, Executive |
| Peter Fuhrken | Director |
| Jeff Goater | Director |
| Jeff Jonas | Director |
| Nick Manusos | Director, Executive |
| Martin Ostrowski | Executive |
| Jonathan Yeh | Director |
Issuer details
Industry: Biotechnology (See others in industry)
Address:
One Broadway 14 Th Floor Kendall Square
Cambridge, MA, 02142
Cambridge, MA, 02142